Etoricoxib


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult: PO Osteoarthritis 30 mg once daily, may increase to 60 mg once daily as necessary. Ankylosing spondylitis; Rheumatoid arthritis 60 mg once daily, may increase to 90 mg once daily as necessary. Once patient is clinically stable, may reduce dose to 60 mg once daily. Acute gouty arthritis 120 mg once daily. Max duration: 8 days. Pain and inflammation associated with dental surgery 90 mg once daily. Max duration: 3 days.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Patient with active peptic ulceration or gastrointestinal bleeding, inflammatory bowel disease, congestive heart failure (NYHA II-IV), uncontrolled hypertension or with persistently high blood pressure (>140/90 mmHg), ischaemic heart disease, peripheral arterial disease, cerebrovascular disease, history of bronchospasm, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria or allergic-type reactions after taking aspirin, NSAIDs including COX-2 inhibitors. Children and adolescent <16 years. Renal (CrCl <30 mL/min) and severe hepatic (Child-Pugh ≥10) impairment. Pregnancy.
Special Precautions
Patient with history of gastrointestinal disease (e.g. ulceration, gastrointestinal bleeding), with risk factors for cardiovascular events (e.g. hyperlipidaemia, hypertension, diabetes mellitus, smoking), uncompensated heart failure, cirrhosis, history of cardiac failure, left ventricular dysfunction, pre-existing oedema, dehydration. Mild to moderate hepatic impairment. Elderly. Lactation. Patient Counselling This drug may cause dizziness, vertigo or somnolence, if affected, do not drive or operate machinery. Monitoring Parameters Monitor blood pressure prior to and during therapy, and periodically thereafter.
Adverse Reactions
Significant: Fluid retention, oedema, hypertension, increased ALT or AST, hypersensitivity reactions including anaphylaxis and angioedema. Cardiac disorders: Palpitations, arrhythmia. Gastrointestinal disorders: Abdominal pain, constipation, flatulence, gastritis, heartburn, diarrhoea, dyspepsia, nausea, vomiting, oesophagitis, oral ulcer. General disorders and administration site conditions: Asthenia, flu-like disease. Infections and infestations: Alveolar osteitis. Nervous system disorders: Headache. Respiratory, thoracic and mediastinal disorders: Bronchospasm.
Potentially Fatal: Gastrointestinal perforations, ulcers or bleedings, exfoliative dermatitis, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN).
Drug Interactions
Increased INR with anticoagulants (e.g. warfarin). May decrease effect of diuretics and antihypertensive agents. Concomitant use with ACE inhibitor or angiotensin II antagonist may further deteriorate renal function. May increase rate of gastrointestinal ulceration with concomitant low dose acetylsalicylic acid. Increased plasma concentrations of ethinylestradiol, lithium, methotrexate, and other drugs metabolised by human sulfotransferases (e.g. oral salbutamol, minoxidil). Decreased plasma concentrations with rifampicin.
ATC Classification
M01AH05 - etoricoxib ; Belongs to the class of non-steroidal antiinflammatory and antirheumatic products, coxibs.
Disclaimer: This information is independently developed by CIMS based on etoricoxib from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in